Immunovant Sciences
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Immunovant Sciences sits in the top decile of US sponsors by registered trial count (#934 of 15,742 sponsors by registered trial count).
Immunovant Sciences: 15 sponsored US clinical trials, 6 recruiting.
Immunovant Sciences sponsors 15 registered US clinical trials on ClinicalTrials.gov, 6 of them currently recruiting, and 2 completed. 5 of these trials are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Thyroid Eye Disease, with 2 trials.
Top-decile sponsor footprint
Immunovant Sciences ranks in the top decile of sponsors by registered trial count (#934 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
15 total, page 1 of 1
Efficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease Activity
NCT06979531
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
NCT07018323
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
NCT07039916
IMVT-1402 in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT07032662
A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)
NCT06980805
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
NCT06727604
A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis
NCT06754462
Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease
NCT05524571
To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP
NCT05581199
Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease
NCT05517447
Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis
NCT05403541
Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease
NCT05517421
To Assess the Efficacy and Safety of RVT-1401 in the Treatment of Warm Autoimmune Hemolytic Anemia (ASCEND-WAIHA).
NCT04253236
ASCEND GO-2: Study of RVT-1401 for the Treatment of Participants With Active, Moderate to Severe Graves' Ophthalmopathy ( GO )
NCT03938545
A Study of RVT-1401 in Myasthenia Gravis (MG) Patients
NCT03863080
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 10 |
| Phase 3 | 5 |
What is open in the Immunovant Sciences pipeline
6 recruiting of 15 indexed (40% open); 2 completed (13%).
Phase mix: 5 late (III/IV) vs 10 early (I/II) (early-phase heavy).
Top condition: Thyroid Eye Disease (2 trials), 8 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Immunovant Sciences: open-pipeline peers nationwide
Peers matched on 15 registered trials and 40% open enrollment, not the therapeutic-area sidebar.
Immunovant Sciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 15 trials (± recruiting share)
- Allakos · 15 trials · 0% recruiting
- Arbor Research Collaborative for Health · 15 trials · 33% recruiting
- Arena Pharmaceuticals · 15 trials · 0% recruiting
- Arrowhead Pharmaceuticals · 15 trials · 20% recruiting
Sponsors near 40% open enrollment (± trial volume)
- Ad scientiam · 40% recruiting · 5 trials
- Alto Neuroscience · 40% recruiting · 10 trials
- Bonafide Health · 40% recruiting · 5 trials
- Brooks Rehabilitation · 40% recruiting · 5 trials
Related
What to do with this Immunovant Sciences page
15 registered trials is a research-attention snapshot, not an endorsement of Immunovant Sciences or any single study.
- 6 of Immunovant Sciences's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Thyroid Eye Disease is the condition Immunovant Sciences studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Thyroid Eye Disease trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Immunovant Sciences pipeline card: 15 registered trials from official public datasets.Report a data error.